S. Novello

发表

Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

S Senan, K. Kerr, S. Novello, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

A randomized phase III trial comparing standard and high-dose pemetrexed as second-line treatment in patients with locally advanced or metastatic non-small-cell lung cancer.

S. Novello, P. Zatloukal, N. Iscoe, 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

Results of screening in early and advanced thoracic malignancies in the EORTC pan-European SPECTAlung platform

T. Gorlia, A. Dingemans, E. Felip, 2022, Scientific Reports.

Chemo-radiotherapy in lung cancer: state of the art with focus on the elderly population.

U. Ricardi, R. Ragona, F. Giglioli, 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

A phase II randomized study evaluating the addition of iniparib to gemcitabine plus cisplatin as first-line therapy for metastatic non-small-cell lung cancer.

G. Scagliotti, E. Felip, A. Santoro, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Women and lung cancer.

E. Baldini, S. Novello, 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

P. V. Van Schil, T. Mok, K. Kerr, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Correction to: "Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up".

P. V. Van Schil, T. Mok, K. Kerr, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase I-II and pharmacokinetic study of gemcitabine combined with oxaliplatin in patients with advanced non-small-cell lung cancer and ovarian carcinoma.

S. Novello, E. Raymond, J. Armand, 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

Original article A three-week schedule of gemcitabine-cisplatin in advanced non-small-cell lung cancer with two different cisplatin dose levels: A phase II randomized trial

G. Scagliotti, C. Gridelli, M. Rinaldi, 2005 .

NGR‐hTNF and Doxorubicin as Second‐Line Treatment of Patients with Small Cell Lung Cancer

A. Santoro, R. Cavina, F. Grossi, 2018, The oncologist.

Associations of Tissue Tumor Mutational Burden and Mutational Status With Clinical Outcomes With Pembrolizumab Plus Chemotherapy Versus Chemotherapy For Metastatic NSCLC

J. Lunceford, M. Ayers, B. Halmos, 2022, JTO clinical and research reports.

Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

P. V. Van Schil, E. Smit, T. Mok, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

P. V. Van Schil, T. Mok, K. Kerr, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Treatment of advanced non-small cell lung cancer.

G. Scagliotti, C. Gridelli, D. Galetta, 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

LBA10 Sotorasib versus docetaxel for previously treated non-small cell lung cancer with KRAS G12C mutation: CodeBreaK 200 phase III study

A. Dingemans, J. Mazières, M. Schuler, 2022, Annals of Oncology.

Outcome of advanced NSCLC patients harboring sensitizing EGFR mutations randomized to EGFR tyrosine kinase inhibitors or chemotherapy as first-line treatment: a meta-analysis.

G. Scagliotti, A. Ceribelli, M. Milella, 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

ARCTIC: durvalumab with or without tremelimumab as third-line or later treatment of metastatic non-small-cell lung cancer.

N. Reinmuth, D. Planchard, R. Soo, 2020, Annals of oncology : official journal of the European Society for Medical Oncology.

Pemetrexed-based chemotherapy in patients with advanced, ALK-positive non-small cell lung cancer.

G. Scagliotti, M. Mino‐Kenudson, J. Engelman, 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

Alectinib versus crizotinib in treatment-naive anaplastic lymphoma kinase-positive (ALK+) non-small-cell lung cancer: CNS efficacy results from the ALEX study

A. Shaw, S. Ou, T. Mok, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Epidermal growth factor receptor overexpression correlates with a poor prognosis in completely resected non-small-cell lung cancer.

V Torri, V. Torri, G. Scagliotti, 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

Final efficacy and safety data, and exploratory molecular profiling from the phase III ALUR study of alectinib versus chemotherapy in crizotinib-pretreated ALK-positive non-small-cell lung cancer

R. Dziadziuszko, J. Mazières, K. Trunzer, 2022, ESMO open.

Three-year findings of an early lung cancer detection feasibility study with low-dose spiral computed tomography in heavy smokers.

G Cortese, C Fava, G. Scagliotti, 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

2O IMpower010: Biomarkers of disease-free survival (DFS) in a phase III study of atezolizumab (atezo) vs best supportive care (BSC) after adjuvant chemotherapy in stage IB-IIIA NSCLC

H. Wakelee, C. Zhou, M. Das Thakur, 2021, Annals of Oncology.

1O IMpower010: ctDNA status in patients (pts) with resected NSCLC who received adjuvant chemotherapy (chemo) followed by atezolizumab (atezo) or best supportive care (BSC)

B. Nabet, H. Wakelee, J. Hamm, 2022, Immuno-Oncology and Technology.

The elderly patient individualized chemotherapy (EPIC) trial, a study for an aged population of non-small cell lung cancer

V. Torri, G. Scagliotti, D. Galetta, 2019, Annals of Oncology.

989P Sotorasib in advanced KRAS p.G12C-mutated non-small cell lung cancer (NSCLC): Safety and efficacy data from the global expanded access program (EAP)

M. Awad, J. Stevenson, J. Bauman, 2022, Annals of Oncology.

Ramucirumab plus erlotinib versus placebo plus erlotinib in previously untreated EGFR-mutated metastatic non-small-cell lung cancer (RELAY): exploratory analysis of next-generation sequencing results

M. Nishio, M. Reck, E. Garon, 2023, ESMO open.

Consensus clustering methodology to improve molecular stratification of non-small cell lung cancer

G. Scagliotti, F. Bussolino, D. Corà, 2023, Scientific Reports.

ARCTIC: Durvalumab + tremelimumab and durvalumab monotherapy vs SoC in≥3L advanced NSCLC treatment.

N. Reinmuth, D. Planchard, R. Soo, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Pemetrexed-based chemotherapy in patients with advanced, ALK-positive non-small cell lung cancer

G. Scagliotti, M. Mino‐Kenudson, J. Engelman, 2021 .

LBA4 Randomized phase III study of first-line selpercatinib versus chemotherapy and pembrolizumab in RET fusion-positive NSCLC

S. Novello, K. Park, J. Wolf, 2023, Annals of Oncology.